Biochemical and Cellular Oncogenesis – BCO
The Biochemical and Cellular Oncogenesis (BCO) study section focuses on the proteins and signal transduction pathways that drive the initiation or early stages of human cancer. A distinguishing characteristic of applications are the use of multidisciplinary approaches to characterize the structure, function, and modulation of oncogenic proteins that participate in and integrate diverse signaling networks.
The membership panel is a list of chartered members only.
- Characterization of oncogenes and tumor suppressors in tumor initiation and transformation.
- Effects of post-translational modifications on protein stability, structure and function in the context of cancer.
- Integration of aberrant or deregulated protein signaling pathways in tumor initiation, including dissection of protein complexes and signaling networks.
- Protein target discovery within oncogenic signaling pathways.
- Chemical biology and genetic approaches to interrogate protein-protein interactions or signaling pathway function in early tumorigenesis.
- Role of cell cycle pathways in early tumorigenesis.
- DNA damage, repair, mutagenesis and replication stress during tumor initiation and malignant transformation.
Shared Interests and Overlaps
There are shared interests with Gene Regulation in Cancer (GRIC) in the role of oncogenes and tumor suppressors in tumorigenesis. Applications that focus on gene regulatory mechanisms and epigenetics may be reviewed in GRIC. Applications that focus on tumor initiation, signal transduction and post-translational modifications may be reviewed in BCO.
There are shared interests with Cancer Cell Biology (CCB) in basic mechanisms of cell cycle pathways, signal transduction and tumorigenesis. Applications that mainly focus on mechanisms associated with tumor metabolism, stress and cell death may be reviewed in CCB. Applications that mainly focus on tumor initiation and post-translational modifications may be reviewed in BCO.
There are shared interests with Mechanisms of Cancer Therapeutics A, B, C in mechanisms involved in early stages of tumorigenesis. Applications that focus on mechanistic studies of the effects of anti-neoplastic agents as therapeutics on early tumorigenesis may be reviewed in the MCTs. Applications that focus on using anti-neoplastic agents as tools to examine basic mechanisms involved in early tumorigenesis may be reviewed in BCO.
There are shared interests with Cellular Signaling and Regulatory Systems (CSRS) in cell cycle and signaling pathways. Applications that focus on the normal, or cancer cells as a model to understand basic mechanisms underlying these processes are reviewed in CSRS. Applications that focus on oncogenic transformation and tumor initiation may be reviewed in BCO.
There are shared interests with Cancer Genetics (CG) in studies of genomic instability caused by DNA damage in carcinogenesis. Applications that study genomic instability with a focus on DNA damage and repair during tumor initiation will be assigned to BCO. Applications that focus on genetic and epigenetic aspects of genomic instability may be assigned to CG.